Abvc biopharma announces completion of subject treatment for interim analysis on adhd phase iib clinical study

Fremont, ca, dec. 07, 2023 (globe newswire) -- via newmediawire –  abvc biopharma, inc . (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced an update on the company's eight-week long adhd phase ii part ii clinical study taking place at the university of california san francisco (ucsf) medical center and five taiwanese medical centers. a total of 94 subjects were screened, out of which 69 enrolled in the study; 60 subjects completed the eight-week study.
ABVC Ratings Summary
ABVC Quant Ranking